Humanisation And Pre-clinical Validation Of A Therapeutic Anti-cancer Antibody
Funder
National Health and Medical Research Council
Funding Amount
$699,136.00
Summary
This grant will develop a novel antibody against a protease expressed on cancer cells. Preclinical studies, and antibody humanisation, will be performed. This project will also provide vital information on optimal therapeutic approaches with the antibody that can be ultimately taken into human trials.
We have discovered a single tumour factor which causes cancer cachexia, a wasting condition that is one of the worst complications of malignancy, for which there is no current effective treatment. We have developed antibodies which effectively block this condition in preclinical models and have produced human/humanised version of this. This application is to characterise these human antibodies to allow us proceed to clinical trials.
Alpha-particles linked to recombinant antibodies targeting tumour cells have potential to effectively treat tumours while minimising normal tissue side effects. We will explore a novel alpha-particle therapy approach to solid tumours, by delivering 225Ac directly into tumour cells, or into cells that support the tumour (microenvironment). This approach will hopefully result in development of a new approach to treatment of cancers that are resistant to conventional therapies.
ADAM Metalloprotease Inhibition For Treatment Of Colorectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$770,925.00
Summary
Colorectal cancer (CRC) causes over 4000 deaths/year, typically from developing drug resistance and spreading to other organs (metastasis). These processes involve tumour cells called cancer stem cells (CSCs), which rely on specific cell surface proteins for survival and function. We are developing antibodies against one of these type of proteins, to test in mouse models of CRC. These already show promise in targeting CSCs and inhibiting drug-resistance and metastasis in mice.
How ribosomal protein loss affects cell fate. This project aims to challenge the dogma that the ribosome behaves only as a ‘‘house-keeper’’. Ribosomal protein (RP) mutations should, and often do, result in reduced cell growth and stunted animal development. Depletion of RPs in Drosophila blood cells impair stem cells and cause massive tissue overgrowth. This suggests RPs are involved in cell fate determination, which this project will research using genetic models. As ribosomal function is funda ....How ribosomal protein loss affects cell fate. This project aims to challenge the dogma that the ribosome behaves only as a ‘‘house-keeper’’. Ribosomal protein (RP) mutations should, and often do, result in reduced cell growth and stunted animal development. Depletion of RPs in Drosophila blood cells impair stem cells and cause massive tissue overgrowth. This suggests RPs are involved in cell fate determination, which this project will research using genetic models. As ribosomal function is fundamental to the development of all living organisms, this work could have wide implications for understanding all biology – from microbes, insects and plants to humans.Read moreRead less